ALNYLAM PHARMACEUTICALS, INC. (33) | Uncategorized (12)

Recent Contracts

Letter Agreement between the Registrant and (Filed With SEC on April 28, 2022)
Letter Agreement effective as of October 26, 2021 between the Company and John M. Maraganore, Ph.D (Filed With SEC on October 28, 2021)
Letter Agreement between the Registrant and Laurie B. Keating dated September 6, 2021 (Filed With SEC on October 28, 2021)
Sponsored Research Agreement dated as of July 27, 2009 by and among the (Filed With SEC on August 3, 2021)
Amendment No. 1 to Sponsored Research Agreement dated as of July 27, 2009 (Filed With SEC on August 3, 2021)
Supplemental Agreement effective July 27, 2009 by and among the (Filed With SEC on August 3, 2021)
Co-Development Agreement between the Registrant and BXLS (Filed With SEC on November 5, 2020)
First Amendment to (Filed With SEC on November 5, 2020)
Letter Agreement between the Registrant and Barry E. Greene dated August 26, 2020 (Filed With SEC on November 5, 2020)
Patent Cross-License Agreement dated April 3, 2020 between Dicerna Pharmaceuticals, Inc. and the Registrant (Filed With SEC on August 6, 2020)
Investor Agreement dated as of April 8, 2019 by and between the Registrant and Regeneron Pharmaceuticals, Inc (Filed With SEC on August 6, 2019)
Amended and Restated Investor Agreement dated as of April 8, 2019 by and between the Registrant and Genzyme Corporation (Filed With SEC on August 6, 2019)